Microscopic Polyangiitis (MPA)
10
4
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
10.0%
1 terminated out of 10 trials
80.0%
-6.5% vs benchmark
40%
4 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis
Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
Vasculitis Pregnancy Registry
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Special Drug Use-results Survey for Long-term Use（Avacopan）
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA
Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
The ANCA Vasculitis Questionnaire (AAV-PRO©)